{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:48:40Z","timestamp":1792201720758,"version":"4.4.0"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2024,9,3]]},"abstract":"<jats:p xml:lang=\"en\">Mavacamten is the first and only cardiac myosin inhibitor approved in 5 continents for the treatment of adults with symptomatic New York Heart Association class II and III obstructive hypertrophic cardiomyopathy. An evidence\u2010based rationale was used to develop individualized mavacamten dosing, guided by commonly used clinical parameters. Echocardiography is recommended as part of routine clinical assessment of patients with hypertrophic cardiomyopathy, and left ventricular (LV) outflow tract gradient and LV ejection fraction are parameters that can be readily assessed and monitored by echocardiography. Therefore, an echocardiography\u2010based, clinically guided dose\u2010titration strategy was developed to optimize patient benefit from mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy while minimizing the risk of LV ejection fraction reduction. Results from clinical trials paired with extensive modeling and simulation analyses support a dose\u2010titration and monitoring strategy based on serial echocardiographic measures of Valsalva LV outflow tract gradient and LV ejection fraction. This dosing approach allows for the identification of the lowest individualized mavacamten dose and exposure required to provide improvements in LV outflow tract obstruction, functional capacity, and symptoms. Mavacamten is primarily metabolized by CYP2C19 (cytochrome P450 2C19), and CYP2C19 metabolizer phenotype has an effect on mavacamten exposure. Therefore, this approach has also been demonstrated to provide a favorable safety profile irrespective of patients' CYP2C19 metabolizer status. The dose\u2010titration strategy includes additional considerations for the potential onset of systolic dysfunction in the context of intercurrent illness, and for the potential of drug\u2013drug interactions with inhibitors and substrates of cytochrome P450 enzymes. This posology is reflected in the mavacamten US prescribing information.<\/jats:p>","DOI":"10.1161\/jaha.124.033767","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T06:31:21Z","timestamp":1724913081000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response"],"prefix":"10.1161","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-8495","authenticated-orcid":false,"given":"Anjali T.","family":"Owens","sequence":"first","affiliation":[{"name":"Perelman School of Medicine","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0010-9797","authenticated-orcid":false,"given":"Milind","family":"Desai","sequence":"additional","affiliation":[{"name":"Cleveland Clinic","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-3022","authenticated-orcid":false,"given":"Matthew T.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine","place":["Stanford, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rodonski","sequence":"additional","affiliation":[{"name":"Ascension Saint Thomas Heart West","place":["Nashville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6659-3687","authenticated-orcid":false,"given":"Samira","family":"Merali","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1912-1710","authenticated-orcid":false,"given":"Amy J.","family":"Sehnert","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4473-6725","authenticated-orcid":false,"given":"Sara","family":"Saberi","sequence":"additional","affiliation":[{"name":"University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","volume-title":"Prescribing Information","author":"CAMZYOS (mavacamten)","year":"2024","unstructured":"CAMZYOS (mavacamten) . Prescribing Information. Princeton, NJ: Bristol\u2010Myers Squibb Company; 2024. Accessed June 14, 2024. https:\/\/packageinserts.bms.com\/pi\/pi_camzyos.pdf."},{"key":"e_1_3_2_3_2","volume-title":"Summary of Product Characteristics","author":"CAMZYOS (mavacamten)","year":"2023","unstructured":"CAMZYOS (mavacamten) . Summary of Product Characteristics. Dublin, Ireland: Bristol\u2010Myers Squibb Pharma EEIG; 2023. Accessed April 22, 2024. https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/camzyos\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1809540115"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.776815"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1495856"},{"key":"e_1_3_2_7_2","unstructured":"Perera V Gretler DD Seroogy JD Chiang M Palmisano M Florea V. Pharmacokinetic drug\u2010drug interaction study of mavacamten with verapamil in healthy subjects. Poster presented at: Annual College of Clinical Pharmacology (ACCP) Annual Meeting. North Bethesda MD USA. September 25\u2013272022."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1691\/ph.2018.8689"},{"key":"e_1_3_2_9_2","unstructured":"Centre for Drug Evaluation and Research . Clinical pharmacology review. Mavacamten. 2022 Accessed December 7 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/214998Orig1s000ClinPharmR.pdf."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001250"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.541"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31793-1"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X1201160126125403"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad3456"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.006853"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.052359"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.09.028"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Garcia\u2010Pavia P Oreziak A Masri A Barriales\u2010Villa R Abraham TP Owens AT Lakdawala NK Saberi S Wang A Wheeler MT et\u00a0al. Long\u2010term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA\u2010long\u2010term extension (LTE) study up to 120\u2009weeks. Oral presentation at: European Society of Cardiology Congress. August 25\u201328 2023.","DOI":"10.1093\/eurheartj\/ehad655.1844"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(24)02344-1"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311059"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3016"},{"key":"e_1_3_2_24_2","unstructured":"Merali S Salinger DH Perera V Thaneer N Back H Seroogy JD Gretler DD Sehnert AJ Palmisano M Roy A. Exposure\u2010response modeling of mavacamten in adults with hypertrophic cardiomyopathy (HCM). Poster presented at: 13th American Conference of Pharmacometrics (ACoP13). Aurora CO USA. October 30\u2013November 2 2022."},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Saberi S Kramer CM Oreziak A Masri A Barriales\u2010Villa R Abraham TP Lakdawala NK Wang A Choudhury L Rader F et\u00a0al. 96\u2010week cardiac magnetic resonance (CMR) results of treatment with mavacamten from the EXPLORER cohort of the MAVA\u2010Long\u2010Term Extension (LTE) study in patients (pts) with obstructive hypertrophic cardiomyopathy (HCM). Poster presented at: American College of Cardiology (ACC)\/World Congress of Cardiology (WCC) 2023. New Orleans LA USA. March 4\u20136; 2023.","DOI":"10.1016\/S0735-1097(23)00770-2"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.04.048"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2021.05.007"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12574-016-0310-8"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000938"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/ejechocard\/jeq063"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2018.01.022"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2022.03.012"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeu291"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2007.126003"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2017.11.017"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/clc.20594"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.5.461"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062534"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3342"},{"key":"e_1_3_2_40_2","unstructured":"Merali S Sehnert AJS David H Roy A Palmisano M Perera V. Modeling and simulation to investigate dose titration regimen for mavacamten in adults with obstructive hypertrophic cardiomyopathy (HCM). Poster presented at: 13th American Conference of Pharmacometrics (ACoP13). Aurora CO USA. October 30\u2013November 2. 2022."},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.03.064"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3030"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.6.691"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-01129-1"},{"key":"e_1_3_2_45_2","volume-title":"Canadian Product Monograph","author":"CAMZYOS (mavacamten)","year":"2022","unstructured":"CAMZYOS (mavacamten) . Canadian Product Monograph. Montreal, Canada: Bristol\u2010Myers Squibb Canada; 2022. Accessed April 22, 2024. https:\/\/www.bms.com\/assets\/bms\/ca\/documents\/productmonograph\/CAMZYOS_EN_PM.pdf"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.029267"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.821306"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2021.17"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1332"},{"key":"e_1_3_2_50_2","volume-title":"REMS patient brochure","author":"CAMZYOS (mavacamten)","year":"2022","unstructured":"CAMZYOS (mavacamten) . REMS patient brochure. Princeton, NJ: Bristol Myers Squibb; 2022. Accessed December 7, 2023. https:\/\/www.camzyosrems.com\/assets\/commercial\/us\/camzyosrems\/en\/pdf\/Camzyos\u2010REMS\u2010Patient\u2010Brochure.pdf"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2298"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3005"},{"key":"e_1_3_2_53_2","volume-title":"CAMZYOS (mavacamten) dosing guide","year":"2022","unstructured":"CAMZYOS (mavacamten) dosing guide. Princeton, NJ: Bristol Myers Squibb; 2022. Accessed December 7, 2023. https:\/\/www.camzyoshcp.com\/dosing\u2010guide."},{"key":"e_1_3_2_54_2","unstructured":"PAXLOVID\u2122 (nirmatrelvir tablets; ritonavir tablets) emergency use authorization fact sheet for healthcare providers. Pfizer Inc. New York NY. Accessed December 7 2023. https:\/\/www.fda.gov\/media\/155050\/download."},{"key":"e_1_3_2_55_2","volume-title":"REMS program overview","author":"CAMZYOS (mavacamten)","year":"2022","unstructured":"CAMZYOS (mavacamten) . REMS program overview. Princeton, NJ: Bristol Myers Squibb; 2022. Accessed December 7, 2023. https:\/\/www.camzyosrems.com\/assets\/commercial\/us\/camzyosrems\/en\/pdf\/Camzyos\u2010REMS\u2010Program\u2010Overview.pdf."}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.124.033767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:04:07Z","timestamp":1769691847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.124.033767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":54,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9,3]]}},"alternative-id":["10.1161\/JAHA.124.033767"],"URL":"https:\/\/doi.org\/10.1161\/jaha.124.033767","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"2024-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e033767"}}